GLUE
Monte Rosa Therapeutics, Inc.
24.76
1 x 24.66
1 x 24.75
bid
ask
+
0.74
3.08%
10:17 AM
timesize
| Ytd | 57.91% | |
| 1y | 423.47% |
23.22
day range
25.22
4.12
52 week range
25.77
| Open | 23.56 | Prev Close | 24.02 | Low | 23.22 | High | 25.22 | Mkt Cap | 2.09B |
| Vol | 296.44K | Avg Vol | 1.09M | EPS | -1.48 | P/E | N/A | Forward P/E | -13.34 |
| Beta | 1.60 | Short Ratio | 18.14 | Inst. Own | 112.69% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 19.26 | 200-d Avg | 16.53 | 1yr Est | 32.33 |
| Income Statement | |||
| Total Revenue | 4.21M | ||
| Revenues (USD) | 4.21M | ||
| Gross Profit | 4.21M | ||
| Operating Expenses | 54.24M | ||
| Research and Development Expense | 44.07M | ||
| Selling, General and Administrative Expense | 10.18M | ||
| Operating Income | -50.03M | ||
| Income Tax Expense | 52.00K | ||
| Net Income | -44.50M | ||
| Net Income Common Stock | -44.50M | ||
| Net Income Common Stock (USD) | -44.50M | ||
| Consolidated Income | -44.50M | ||
| Earnings per Basic Share | -0.45 | ||
| Earnings per Basic Share (USD) | -0.45 | ||
| Earnings per Diluted Share | -0.45 | ||
| Earning Before Interest & Taxes (EBIT) | -44.45M | ||
| Earning Before Interest & Taxes (USD) | -44.45M | ||
| Weighted Average Shares | 99.88M | ||
| Weighted Average Shares Diluted | 99.88M | ||
| Balance Sheet | |||
| Cash and Equivalents | 164.81M | ||
| Cash and Equivalents (USD) | 164.81M | ||
| Investments | 506.36M | ||
| Investments Current | 506.36M | ||
| Trade and Non-Trade Receivables | 4.61M | ||
| Current Assets | 677.55M | ||
| Property, Plant & Equipment Net | 53.10M | ||
| Total Assets | 736.43M | ||
| Debt Current | 4.48M | ||
| Total Debt | 39.06M | ||
| Current Liabilities | 71.04M | ||
| Debt Non-Current | 34.58M | ||
| Total Liabilities | 214.51M | ||
| Accumulated Retained Earnings (Deficit) | -521.72M | ||
| Accumulated Other Comprehensive Income | -4.75M | ||
| Shareholders Equity | 521.92M | ||
| Shareholders Equity (USD) | 521.92M | ||
| Assets Non-Current | 58.88M | ||
| Total Debt (USD) | 39.06M | ||
| Deferred Revenue | 136.69M | ||
| Liabilities Non-Current | 143.48M | ||
| Trade and Non-Trade Payables | 7.90M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 2.03M | ||
| Net Cash Flow from Financing | 328.34M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 29.97M | ||
| Capital Expenditure | -1.87M | ||
| Issuance (Purchase) of Equity Shares | 328.82M | ||
| Net Cash Flow from Investing | -261.00M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -259.13M | ||
| Net Cash Flow from Operations | -37.37M | ||
| Share Based Compensation | 5.95M | ||